Genmab: Start of Ofatumumab Phase III Head to Head Study in Follicular Lymphoma

27-Oct-2010 - Denmark

Genmab A/S announced the start of a Phase III study of single agent ofatumumab compared to single agent rituximab in patients with follicular non-Hodgkin’s lymphoma (NHL) that has relapsed at least 6 months after completion of treatment with a rituximab-containing regimen to which they responded.

Approximately 516 patients in this open-label study will be randomized to receive ofatumumab (1000 mg) or rituximab (375 mg/m2) by intravenous infusion for four weekly doses. Patients who have stable or responsive disease will then receive single infusions of ofatumumab or rituximab every two months for four additional doses for a total of eight doses over nine months. The primary endpoint of the study is progression free survival.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances